HB Wealth Management LLC Invests $35,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX)

HB Wealth Management LLC bought a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $35,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Headlands Technologies LLC acquired a new position in shares of Heron Therapeutics during the first quarter valued at about $30,000. Susquehanna Fundamental Investments LLC bought a new stake in Heron Therapeutics in the 1st quarter valued at about $32,000. Valeo Financial Advisors LLC acquired a new position in Heron Therapeutics during the 2nd quarter worth approximately $45,000. Capital Investment Counsel Inc raised its stake in Heron Therapeutics by 27.2% during the 2nd quarter. Capital Investment Counsel Inc now owns 14,625 shares of the biotechnology company’s stock worth $51,000 after buying an additional 3,125 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 4,617 shares in the last quarter. 80.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HRTX. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a research report on Wednesday, August 7th. Rodman & Renshaw began coverage on shares of Heron Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 price target for the company.

Heron Therapeutics Stock Performance

HRTX stock opened at $1.93 on Friday. The business has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $2.86. The company has a market capitalization of $290.76 million, a P/E ratio of -3.16 and a beta of 1.81. Heron Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $36.02 million during the quarter, compared to the consensus estimate of $35.35 million. During the same quarter last year, the firm posted ($0.35) earnings per share. As a group, sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.